Crossmark

Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy – an analysis of Swiss pharmacovigilance data

Crossref DOI link: https://doi.org/10.1007/s00228-025-03968-7

Published Online: 2026-02-24

Published Print: 2026-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Stäuble, Céline K. https://orcid.org/0000-0002-2437-4803
Toma, Valeriu

Stammschulte, Thomas

Allemann, Samuel S.

Meyer zu Schwabedissen, Henriette E.
License Information

Text and Data Mining valid from 2026-02-24

Version of Record valid from 2026-02-24
More Information

Article History

Received: 23 July 2025

Accepted: 19 September 2025

First Online: 24 February 2026

Declarations

:

: This study did not fulfill the criteria for research according to the Swiss Human Research Act and therefore was exempt from ethics approval from a competent cantonal ethics committee. This research study was conducted retrospectively from anonymously collected data of individual case safety reports obtained from the Swissmedic database. It was ensured that all data collected was fully anonymized and handled in compliance with Swiss data protection regulations, thereby adhering to ethical research standards.

: Consent was not required as all information analysed and reported is fully anonymized and not traceable to an individual.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below